Gerresheimer Logo
DE000A0LD6E6
A0LD6E
GXI.DE

Gerresheimer

Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Gerresheimer rises after stronger quarterly results and optimistic outlook

    Gerresheimer shares climbed by more than three percent after preliminary third-quarter results. Revenue beat market expectations by about six percent, while operating profit largely met expectations. Management said it was optimistic about a stronger final quarter. For the previous year the group reports a loss of almost €319 million due to large write-downs; a return to the SDAX is being discussed again in light of the recovery. » Mere på finanzen.net


  • Gerresheimer grows in third quarter despite stagnant adjusted EBITDA

    Gerresheimer increased revenue in the third quarter by 8% to €605 million; adjusted EBITDA remained at €103 million, just behind the prior year (€106m). In the first nine months, inventory reduction and weaker businesses in tubular glass Europe and container glass weighed on adjusted EBITDA. The group expects a stronger fourth quarter and is advancing the sale of its primary plastic packaging business (PPP); closing is expected in Q1 2027. » Mere på wiwo.de


  • Gerresheimer completes sale of Centor to Apax Partners

    Gerresheimer has completed the sale of its US business Centor to Apax Partners; the proceeds are to be used primarily to reduce debt. The separation of the Primary Packaging Plastics division is to take place in the first half of 2027. After the transaction, which is part of a portfolio shift toward primary packaging and drug-delivery systems, the share price fell intraday by up to 3.35 percent. » Mere på finanzen.net


  • Gerresheimer increases adjusted EBITDA significantly in second quarter and plans sale of Centor

    Gerresheimer reports operational improvements in preliminary Q2 results: revenue €578m (adjusted €614m prior year) and adjusted EBITDA €102m (adjusted €126m prior year). Adjusted EBITDA is more than 50% above the previous quarter, which the CFO says is a sign that the transformation program is taking effect. To reduce debt, the US subsidiary Centor and the primary packaging plastics business are to be sold; deals are expected shortly. Gerresheimer expects to publish final Q2 and H1 figures by the end of November. » Mere på deraktionaer.de


  • Gerresheimer shows clear operational recovery in second quarter

    In the second quarter, revenue rose quarter-on-quarter by 10.5% to €578 million, adjusted EBITDA climbed by over 50% to €102 million and the operating margin improved to 17.6%. Compared with the previous year, however, revenue and EBITDA remain below the 2025 level, so the half-year result is slightly down. The full-year guidance was lowered to the lower half of the previous revenue range (€2.3–2.4 billion) and to an adjusted EBITDA margin of 17–18%, while the planned sale of Centor and the plastic packaging business to Apax (enterprise value around €1.5 billion) is intended to help reduce debt. If the recovery continues and the targets are met, the company sees significant turnaround potential after the share-price crash. » Mere på finanzen.net

I 2025 har Gerresheimer allerede udloddet 0,04 € i udbytte. Den seneste udlodning fandt sted i juni 2025.

Virksomhedstal

I det seneste kvartal havde Gerresheimer en omsætning på 474,94 mio. € og et nettoresultat på -98,32 mio. €
(EUR) februar 2026
YoY
Omsætning 474,94 mio. -
Bruttofortjeneste 49,26 mio. -
Nettoresultat -98,32 mio. -
EBITDA 9,56 mio. -

Fundamentale data

Nøgletal Værdi
Markedsværdi
1,08 mia. €
Antal aktier
34,54 mio.
Højeste/laveste i 52 uger
34,20 € - 14,83 €
Udbytte Nej
Beta
0,47
P/E (PE Ratio)
-2,69
PEG (PEG Ratio)
0,01
K/I (PB Ratio)
1,13
P/S (PS Ratio)
0,47

Virksomhedsprofil

Gerresheimer AG og dets datterselskaber fremstiller og sælger emballageprodukter samt lægemiddelafgivelsessystemer og -løsninger over hele verden. Virksomheden er organiseret i divisionerne Plastics & Devices, Primary Packaging Glass og Advanced Technologies. Plastics & Devices-divisionen tilbyder lægemiddelafgivelsessystemer, herunder inhalatorer, insulinpensystemer, fyldbare sprøjter og diagnostiske systemer til farma-, biotek-, diagnostik- og medicinteknikindustrien; beholdere og lukninger, PET-flasker, øjendråbeflasker, næsespray, forstøvere, applikatorer og tilbehør til faste, flydende og oftalmiske anvendelser; samt flasker og beholdere til kosttilskud. Primary Packaging Glass-divisionen tilbyder primær glasemballage til farma- og kosmetikindustrien, såsom infusions-, dråbe- og sirupsflasker; injektionshætteglas, ampuller og patroner; miniflasker og glasbeholdere til flydende fødevarer, krydderier og spiritus; samt emballageløsninger til parfumer, deodoranter, hudplejeprodukter og wellnessprodukter, og til skønheds- og farmaceutiske produkter. Advanced Technologies-divisionen udvikler intelligente lægemiddelafgivelsessystemer, såsom mikropumper, der bruges til selvadministration af medicin mod Parkinsons sygdom eller hjertesvigt til farmaceutiske og bioteknologiske kunder. Virksomheden blev grundlagt i 1864 og har hovedkvarter i Düsseldorf, Tyskland.

Navn
Gerresheimer
CEO
Uwe Ferdinand Röhrhoff
Hjemsted Düsseldorf, nw
Tyskland
Websted
Sektor
Sundhed
Branche
Sundhedsteknologi
Børsnotering
11.06.2007
Medarbejdere 13.301

Tickersymboler

Børs Symbol
XETRA
GXI.DE
Pnk
GRRMF
SIX
GXI.SW
Frankfurt
GXI.F
Düsseldorf
GXI.DU
Hamburg
GXI.HM
London
0NTI.L
München
GXI.MU
Wien
GXI.VI
🍪

Parqet  bruger cookies. Læs mere